

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)



(10) International Publication Number
WO 2023/081901 A1

(51) International Patent Classification:

A61K 35/545 (2015.01) A61P 37/00 (2006.01)
A61K 35/17 (2015.01) A61P 35/00 (2006.01)
A61K 39/00 (2006.01) A61P 31/12 (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2022/079419

(22) International Filing Date:

07 November 2022 (07.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/263,758 08 November 2021 (08.11.2021) US
63/265,192 09 December 2021 (09.12.2021) US

(71) Applicant: **FATE THERAPEUTICS, INC.** [US/US];
12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(72) Inventors: **GOULDING, John, Charles**; 12278 Scripps
Summit Drive, San Diego, CA 92131 (US). **VALAMEHR,**
Bahram; 12278 Scripps Summit Drive, San Diego, CA

92131 (US). **HOSKING, Martin**; 12278 Scripps Summit
Drive, San Diego, CA 92131 (US). **BJORDAHL, Ryan**;
12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(74) Agent: **GIERING, Jeffery C.**; Greenberg Traurig, LLP,
18565 Jamboree Road, Suite 500, Irvine, California 92612
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

(54) Title: ENGINEERED EFFECTOR CELLS AND METHODS OF ENHANCING UBIQUITOUS TARGETING OF SOLID TUMORS




FIG. 4B

(57) Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

[Continued on next page]

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*